- $98.13m
- $152.41m
- $78.23m
Brief: Optinose Reports Q1 2023 Financial Results And Operational Updates
OptiNose Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Peloton, New Fortress Energy, Qualcomm
U.S. STOCKS ON THE MOVE-Paramount Global, First Horizon, Soligenix
Optinose rises as US FDA accepts chronic sinus treatment for review
Brief: Optinose Announces FDA Acceptance Of Supplemental New Drug Application For XHANCE
Brief: Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Etsy, Qualtrics International, Tcr2 Therapeutics
OptiNose Inc reports results for the quarter ended in December - Earnings Summary
OptiNose Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Optinose Submits Supplemental New Drug Application For Xhance Label Expansion
Brief: Optinose Announces CEO Transition And Business Update
Brief: OptiNose Appoints Paul Spence As Chief Commercial Officer
Brief: OptiNose Announces Departure Of Acting Chief Financial Officer
U.S. STOCKS ON THE MOVE-Blue Water, Domino's Pizza, Tesla
U.S. STOCKS ON THE MOVE-China ADRs, silver stocks, Canadian Solar
Brief: Optinose Announces Pricing Of Public Offering Of Common Stock And Warrants
U.S. STOCKS ON THE MOVE-Imago BioSciences, Gold Fields
Optinose slides on $50 mln stock-and-warrants offering